Boosted production of antibodies that neutralized different SARS-CoV-2 variants in a COVID-19 convalescent following messenger RNA vaccination - a case study.
Fenstad, Mona H.; Ravlo, Erlend; Ianevski, Aleksandr; Starheim, Eirin Johannessen; Wang, Wei; Lysvand, Hilde; Smura, Teemu; Ji, Ping; Kivi, Gaily; Voolaid, Maia-Liisa; Plaan, Kati; Ustav, Mart; Ustav, Mart; Žusinaite, Eva; Tenson, Tanel; Kurg, Reet; Oksenych, Valentyn; Walstad, Kirsti; Nordbø, Svein Arne; Kaarbø, Mari; Ernits, Karin; Bjørås, Magnar; Kainov, Denis
Peer reviewed, Journal article
Published version
Permanent lenke
https://hdl.handle.net/11250/3109274Utgivelsesdato
2023Metadata
Vis full innførselSamlinger
- Institutt for klinisk og molekylær medisin [3554]
- Publikasjoner fra CRIStin - NTNU [38294]
- St. Olavs hospital [2536]
Originalversjon
International Journal of Infectious Diseases. 2023, 137 (Dec), 75-78. 10.1016/j.ijid.2023.10.011Sammendrag
Vaccinated convalescents do not develop severe COVID-19 after infection with new SARS-CoV-2 variants. We questioned how messenger RNA (mRNA) vaccination of convalescents provides protection from emerging virus variants. From the cohort of 71 convalescent plasma donors, we identified a patient who developed immune response to infection with SARS-CoV-2 variant of 20A clade and who subsequently received mRNA vaccine encoding spike (S) protein of strain of 19A clade. We showed that vaccination increased the production of immune cells and anti-S antibodies in the serum. Serum antibodies neutralized not only 19A and 20A, but also 20B, 20H, 21J, and 21K virus variants. One of the serum antibodies (100F8) completely neutralized 20A, 21J, and partially 21K strains. 100F8 was structurally similar to published Ab188 antibody, which recognized non-conserved epitope on the S protein. We proposed that 100F8 and other serum antibodies of the patient which recognized non- and conserved epitopes of the S protein, could have additive or synergistic effects to neutralize various virus variants. Thus, mRNA vaccination could be beneficial for convalescents because it boosts production of neutralizing antibodies with broad-spectrum activity.